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With technettum-ssm radiopharmaceuticals, first pass
radionuclide angiocardiography is of limiteduse for mul-
tiple intervention studies because of the large radiation
burden imposed on the patients. A portable mercury-
195m/gold-195m generator has been developed capable
of producing 17 to 20 mCi aliquots of the short half-life
(30.5 seconds)gold-195min less than 0.5 ml of generator
eluate. Safety of the eluate has been established both in
the experimental animal and in human beings.
Fifteen patients underwent two first pass radionuclide
angiograms with gold-195m, followed by a standard
technetium-99m study. There was a closecorrelation be-
tweenthe left ventricular ejectionfraction measured from
gold and technetium studies (correlation coefficient [r]
= 0.99, standard error of the estimate [SEE] 3.1%).
Interobserverand sequentialreproducibilityofgoldstudies
were excellent (mean variability ± standard deviation
Radionuclide angiocardiography now occupies a major role
in the noninvasive evaluation of patients with cardiac dis-
ease, both at rest (1-4) and under conditions of physiologic
or pharmacologic stress (5-9). The first pass technique of-
fers certain advantages over the multiple gated acquisition
method, in particular with regard to temporal separation of
the cardiac chambers, flexibility of projection and low back-
ground counts outside the chamber of interest (10). In ad-
dition, the short, 30 second data acquisition time does not
require the assumption of a steady state during the 2 to 5
minutes needed for multiple gated acquisition. For this rea-
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[SD] 2.0 ± 2.9 and 0.6 ± 2.7%, respectively). Statistical
reliability of the gold studies, as assessed from the ob-
served left ventricular end-diastoliccounts, matched that
of technetium studies, and similarly, the imagesobtained
from the two radiopharmaceuticals were identical. Re-
sidual count rates 5 minutes after first pass acquisition
with gold were 480 ± 140 counts/s in the whole field of
view, and 50 ± 30 counts/s over the left ventricle, these
values being less than 1% of the residual counts after
technetium.
Accurate, reproducible, high count-rate first pass
studies are obtainable with gold-195m, with a markedly
reduced radiation exposure to the patients. It is now
possible to perform rapid sequential first pass cardiac
imaging studies without the constraints of an unaccept-
ably high radiation burden.
son, the first pass technique is particularly well suited to
studies under conditions of circulatory stress.
A major drawback of the first pass method is the re-
quirement of a separate bolus injection of radionuclide for
each data acquisition point. With currently available techne
tium-99m radiopharmaceuticals, this imposes a limit on the
number of sequential first pass studies that can be performed
because of the increasing radiation exposure to the patient.
Additionally, sequential studies are performed against a re-
sidual radioactive blood pool background from previous
technetium-99m doses, for which corrections must be made.
For such corrections to be valid, the spatial and temporal
distribution of that residue must be constant, which places
restrictions on the interval between studies. To increase the
potential of first pass radionuclide angiography, a radio-
pharmaceutical is required that: I) acts as an intravascular
marker, 2) has a short half-life, thereby reducing radiation
exposure and residual background and permitting more se-
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quential studies to be carried out, and 3) has a photon energy
suitable for imaging with standard, commercially available
cameras.
This report describes the development of a portable gen-
erator to produce the new, short half-life (30.5 seconds)
radiopharmaceutical gold-195m, its validation for use in
clinical practice and initial clinical experience with the agent.
Preparation of the Generator and
Radiopharmaceuticals
Portable generator design (Fig. 1). The decay sequence:
EC 40.5 hours IT 30.5 seconds
Hg-195m ) Au-195m .. Au-195.
where EC = electron capture and IT = isomeric transition,
seemed suitable for incorporation into a portable generator
because the 40.5 hour half-life of the parent mercury is long
enough to allow transportation of the generator from pro-
duction site to the clinical environment. Gold-195m emits
a 262 keY gamma photon in 68% of its decays. This energy
is suitable for imaging with gamma cameras, particularly
the multicrystal type (11). On this basis, a collaborative
research effort between the Departments of Cardiology and
Nuclear Medicine at St. Bartholomew's Hospital and the
Atomic Energy Research Estabishment resulted in the pro-
duction of portable mercury/gold generators for first pass
cardiac studies.
The parent material is prepared on the Harwell variable
energy cyclotron by the reaction:
Au-197 (p, 3n) Hg-195m (12).
Figure 1. The mercury-gold generatordesign. In clinical use, the
flask containing the eluant is sealed for sterility and the column is
surrounded by lead shielding. The elution agent is drawn through
the column by withdrawing the plunger of the I ml syringe. Re-
peated aliquots of gold-195m, 17 to 20 mCi in < 0.5 ml, are
obtained.
The only significant radioactive contaminant is approxi-
mately 3.5% Hg-197m, but this is not a problem as it decays
to stable Au-l97 (12). The mercury parent is then extracted
as previously described (12) and adsorbed on to a suitable
column material to form the generator. Initial generators
used vicinal dithiocellulose (VDTC) as the column material
and elution was carried out with 10 roM sodium cyanide
(NaCN) solution (13) with an elution efficiency of only 10
to 20%. The gold-195m activity in the eluate was 5 to 10%
of the mercury-195m activity on the column because only
47% of the mercury-195m decays to gold-195m while the
remainder decays to mercury-195. Apart from the relatively
low elution efficiency of the column material, another prob-
lem with VDTC-based generators was a mercury break-
through of 1 to 2%, which increased to more than 10% after
approximately 24 hours because of radiation damage (14).
Examination of alternative column materials led to a choice
of thiopropyl sepharose 6B (Pharmacia Chemicals Ltd.),
which has an elution efficiency of approximately 40% and
is not as prone to radiation damage as vicinal dithiocellulose
(VDTC). Columns now in use contain over 100 mCi of
mercury-195m, and are eluted with 2.5 roM sodium cyanide
(NaCN). Mercury breakthrough, measured with gamma ray
spectroscopy using a solid state detector system, is less than
0.01% (14).
Sterility and safety. Sterility and apyrogenicity of eluates
from these current generators have been established in the
conventional manner using broth cultures and the 24 hour
rabbit rectal temperature test.
Because of the presence of potentially toxic materials
(cyanide and mercury) in the eluate, animal experiments
were undertaken to determine the effect of the eluate on
hemodynamics, cyanide levels and blood gases. The results
of these experiments (14,15) showed that plasma cyanide,
plasma thiocyanate and red cell cyanide levels all remained
very low, and within the normal range for non-smoking
adults (16), even after the administration of 20 ml of eluate
with a cyanide concentration of 2.7 roM. This volume is
equivalent to approximately 50 clinical doses of 0.4 ml each.
Experiments (14) also showed that there was no change in
heart rate, blood pressure, electrocardiogram or arterial blood
gases after the administration of 20 ml of eluate.
Studies in Patients
After the animal experiments, a protocol was approved
on November 19, 1981 by the Ethical Committee for Human
Investigation at St. Bartholomew's Hospital for a clinical
study of the radiopharmaceutical.
Patients and Methods
Study patients. A total of 15 patients with a mean age
of 57 years (range 42 to 66) referred for routine first pass
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radionuclide angiography were invited to participate in the
study. Individual patient data and the reason for referral are
shown in Table 1.
Protocol. After informed consent had been obtained,
first pass radionuclide angiography was carried out in the
anterior projection in the standard manner (2,17), using 30
ms framing intervals and a multicrystalgammacamera (Baird
Corporation). A 1.5 inch (3.8 ern) collimator was used for
each study. Immediately before using the generator for the
first time on any day, 5 ml were eluted and discarded to
reduce the concentration of mercury and gold-195 in the
eluate. Similarly, if longer than 10 minutes elapsed between
patient studies, the same precautionary measure was taken.
Each patient initially received two bolus injections of 17 to
20 mCi of gold-195m in a volume of less than 0.5 ml each,
the two gold injections being separated by 5 minutes. Im-
aging was carried out for 30 seconds after each bolus in-
jection. Immediately after acquisition of the second gold
study, static 1 second frames were counted over the cardiac
blood pool at 30 second intervals to determine the magnitude
of residual count rates during the first few minutes. In the
first five patients in the protocol, 10 ml of venous blood
was drawn after the second gold study and plasma and red
cell cyanide levels and plasma thiocyanate levels were mea-
sured using assay techniques previously described by Yesey
et al. (16). Approximately 10 minutes after the second gold
study, each patient underwent a third first pass study with
15 mCi of technetium-99m as pertechnetate, imaging being
performed in an identical manner as in the gold angiograms.
Static 1 second frames were again collected over the cardiac
blood pool at 30 second intervals to allow comparison be-
tween the residual count rates for the two radiopharma-
ceuticals. Heart rate and blood pressure were monitored
during and after each first pass study.
Analysis of angiograms. All radionuclide angiograms
were corrected for instrument dead-time and flood field non-
uniformity (17). A technetium-99m uniform source was used
to correct technetium studies, and a mercury-203 source to
correct gold studies. The mercury-203 has an energy of 279
keY, similar to the energy of gold-195m, and the use of
this allowed for any potential differences in crystal uni-
formity at the higher energy level. All studies were analyzed
in the standard manner, left ventricular ejection fraction
being measured from time-activity curves from a region of
interest over the left ventricle, and images of regional wall
motion being obtained as previously described (2,17). In
Table 1. Individual Patient Data and Reason for Referral for
Radionuclide Angiography
Panent Age(yr) & Sex Reason for Referral
65M Possible left ventricular
aneurysm
2 61M Myocardial infarction after
coronary surgery
3 52M Recent episodes ofpulmonary
edema
4 58M Possible cardiomyopathy
5 65M Coronary artery disease,
supraventricular tachycardia
6 63M Complete heart block,
cardiomegaly
7 66M Possible left ventricular
aneurysm
8 57M Anemia, recent myocardial
infarction
9 42M Dyspnea, mitral valve prolapse
10 48M Myocardial infarction after
coronary surgery
II 56M Inferior myocardial infarction,
cardiac failure
12 51M Complete heart block,
cardiomegaly
13 56M Previous myocardial infarction,
syncopal episodes
14 59M Cardiac cachexia,
cardiomegaly
15 54M Myocardial infarction, previous
coronary surgery
12 patients, gold studies were analyzed separately by two
independent observers. In addition, all gold angiograms were
processed using both observed data and data that had been
corrected for radioactive decay. This latter step was per-
formed to assess how critical the effects of decay of the
gold-195m were on the results.
Statistical methods. Standard linear regression analysis
was performed on the ejection fraction values from gold
and technetium studies and on interobserver and sequential
data. Results are expressed as mean ± standard deviation.
Comparison of paired data was made using a t test on the
slope of the regression.
Results
No patient experienced any ill effects during or after
radionuclide angiography. There were no significant changes
Table 2. Mean Cyanide and Thiocyanate Levels in Five Patients Who Received Two Injections of Gold-195m
Before After Normal Range
Plasma cyanide 0.12 /-Lmol/hter 018/-Lmmoll 0-0 3 urnol/liter
liter
Red cell cyanide 0.96 /-Lmoi/liter 1.5/-Lmoll 0.1-3 /-Lmoi/liter
liter
Plasma thiocyanate 31 /-Lmolliiter 35 /-Lmollliter 30-90 /-Lmolliiter
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Figure 4. Sequential reproduc ibility ejection fraction measure-
ments from gold studies.
Figure 3. Interobserver correlation of ejection fraction measure-
ments from gold studies.
technetium-99m were compared. Mean ± standard devia-
tion end-diastolic counts were 5,040 ± 3,108 and 5,0 II
± 2, 156 for sequential gold studies, and 5,169 ± 1,450
for technetium. These figures indicate similar statistical re-
liability of gold and technet ium first pass radionuclide an-
giograms (10).
Wall motion images. In all patients , subjective inter-
pretation of regional wall motion as normal, hypokinetic or
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in heart rate or blood pressure after administration of gold-
195m, and no significant differences in measurements be-
tween gold and technetium studies were noted .
Cyanide and thiocyanate levels (Table 2), No signif-
icant increases in these levels were seen, and all levels
remained within the normal range described for nonsmokers
(16 ).
Ejection fraction. Figure 2 shows the correlation be-
tween ejection fraction measured from gold and technetium
first pass studies. Over a range of ejection fraction from 8
to 62% there was excellent correlation (r =0.99 ) with a slope
not significantly different from unity. Mean (± SD) left
ventricular ejection fraction was 39.6 ± 16.7% from tech-
netium studies and 38.6 ± 17.2% from gold.
Figure 3 shows the interobserver reproducibility of gold
measurements for a total of 24 patient studies. The repro-
ducibility was equally good for either the first or second
gold angiogram in each sequential pair . Mean interobserver
variability was 2.0 ± 2.9%. Figure 4 shows the sequential
reproducibil ity between first and second gold radionuclide
angiograms for a total of 27 studies, 15 analyzed by one
observer and 12 by the other. Reproducibility was high , and
the mean sequential variability was 0.6 ± 2.7%. In neither
set of reproducibility data was the slope of the regression
significantly different from unity.
There was no consistent error introduced in ejection frac-
tion measurement when using observed rather than corrected
data for gold studies, with ejection fraction 37.3 ± 14.4%
before and 37.9 ± 14.4% after decay correction.
Left ventricular count rates. As an index of the sta-
tistical reliability of the studies, the observed left ventricular
counts in the summed, background corrected , end-diastolic
frame of the representative cycle (2, 17) for gold-195m and
Figure 2. Correlation between left ventricular ejection fraction
(LVEF) obtained with gold and technetium first pass studies .
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Figure 5. Technetium-99m (left) and gold-195m (right) images
from a patient with normal left ventricular function. The end-
systolic frame is shown in each case with the end-diastolic perim-
eter superimposed.
akinetic showed the images from gold and technetium to be
identical. Figures 5 and 6 are examples of wall motion
images obtained with gold and technetium in a patient with
normal left ventricular function and in one with a cardio-
myopathy. Each image shows the end-systolic frame with
the end-diastolic perimeter superimposed. In each case, the
gold image has reproduced the pattern of the technetium
image.
Residual count rates. Decay curves for gold and tech-
netium, from both the whole field of view and from the left
ventricular region of interest, are shown in semilogarithmic
form in Figure 7. There is a sharp contrast between the
persistent high count rates in the blood pool with technetium
several minutes after first pass acquisition has been com-
Figure 6. Technetium-99m (left) and gold-195m (right) images
from a patient with cardiac cachexia and cardiomyopathy. Format
of the images as in Figure 5. Ejection fraction was calculated as
9 and 8%, respectively.
pleted and the rapid decay of gold-195m. Five minutes after
the first pass study, mean ± standard deviation counts/s for
technetium were 58,500 ± 11,400 in the whole field and
8,400 ± 2,200 in the left ventricle, compared with 480 ±
140 and 50 ± 30, respectively, for gold.
Initial clinical trial. With the safety of the generator
established and the technique validated, the suitability of
the radiopharmaceutical for rapid, sequential first pass im-
aging under conditions of circulatory stress was tested. Fig-
ure 8 shows sequentially obtained wall motion images and
ejection fraction values from a patient with triple vessel
coronary artery disease. Images were obtained at rest, after
3 minutes and after 6 minutes of graded upright bicycle
exercise, at peak symptom-limited exercise, immediately
------------------
Figure 7. Decay curves for technetium
and gold in semilogarithmic form, show-
ing measured counts/s from the end of the
first pass study to 6 minutes after acqui-
sition. Counts/s for the whole field and
for the left ventricular (LV) region of in-
terest are shown.
1 x 104
Log (mean
counts/
second) 1 x 103
1 x 10 2
1 x 10 1
0 2.5 5.0 7.5
Time after injection (min)
Au -- 195m Whole field --
Au - 195m LV region ------
Tc -- 99m Whole field
Tc - 99m LV region
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REST 3 MINUTE EXERCISE 6 MINUTE EXERC ISE
LVEF 511 LVEF 50 1. LVEF 37l
PEAK EXERCISE (8~min)
LVEF 32 7.
IMMEDIATE POST-
EXERCISE LVEF 3 7%
2 MINUTE RECOVERY
LVEF 55 7.
Figure8. Images of regional wall motion obtained
with gold-195m at rest, at various stages of bicycle
exercise and after recovery in a patient with triple
vessel coronary artery disease. Each image repre-
sents the end-systolic frame with the end-diastolic
perimeter superimposed. Values for left ventricular
ejection fraction (LVEF) are also shown. Deterio-
ration of left ventricular function and subsequent
normalization are demonstrated.
after exercise and after 2 minutes of recovery. Deterioration
in left ventricular function during exercise and the normal-
ization after recovery are apparent.
Discussion
Available radionuclides for sequential first pass an-
giographic studies. The full potential of first pass radio-
nuclide angiography cannot be realized with technetium-
99m radiopharmaceuticals because of the long (6 hours)
physical half-life of the radionuclide, which leads to con-
tinued radiation exposure to the patient long after data ac-
quisition has ended and to residual blood pool radioactivity.
This imposes severe restrictions on the ability to obtain
multiple sequential measurements of cardiac function with
this technique. The ideal radionuclide for first pass studies
should only expose the patient to radiation during data ac-
quisition, allowing multiple data points to be collected with
minimal radiation dose and residual blood pool background
activity. Other short half-life radionuclides for cardiac use
have been produced. The generator described by Blau et al.
(18) produced barium-137m, with a half-life of less than 3
minutes from a cesium-137parent, but the 662 keV photon
energy of the barium was too great for use with scintillation
cameras. Krypton-81m, with an energy of 190 keY and a
half-life of 13 seconds, is produced from a rubidium-81
parent in generator form (19). This agent is not suitable for
left heart studies as it is eliminated through the lungs. Kryp-
ton-81 m has been used for the study of right ventricular
function (20), but its main use is for the continuous as-
sessmentof myocardialperfusionvia an aortic infusioncath-
eter (19). The osmium-191 mJiridium-191 m generator de-
scribed by Cheng et al. (21) has a shelf life of approximately
2 weeks, which permits its use in the clinical environment.
The 4.96 second half-life of iridium-191mis ideal for rapid,
sequential first pass studies in infants and children (22) and
preliminary studies (22) have suggested it may be used in
adults. It remains to be seen whether statistically reliable
measurements of left ventricular function may be obtained
in adults from peripheral venous injections of this agent,
particularly in patients with cardiac failure and prolonged
circulationtimes. Tantalum-178, with a half-lifeof9.3 min-
utes, is also produced in generator form from a tungsten-
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178 parent (23), but the isotope has a low 55 to 65 keY
energy, outside the optimal range for gamma cameras.
Safety of mercury-195m/gold-195m generator eluate.
The potential suitability of the radionuclide pair mercury-
195m/gold-195m for use as a generator was first noticed by
Lebowitz and Richards (24). The 40.5 hour half-life of the
parent mercury permits the use of the generator over 2 to
3 days, whereas the 30.5 second half-life of the gold is long
enough to permit evaluation of left heart dynamics from
peripheral venous injections, but short enough to allow rapid
sequential studies to be performed.
The safety of the generator eluate had been established
in experimental animals and in human patients with no de-
monstrable, significant increases in cyanide or thiocyanate
levels, even after as much as 20 ml of the eluate (14). This
may be put into perspective by comparing these levels with
the levels experienced in patients receiving sodium nitro-
prusside infusions for hypotensive anesthesia for up to 168
minutes. The maximal plasma cyanide level was 20.5 Jlomoll
liter, thiocyanate level was 172 Jlomollliter and red cell cy-
anide reached 212 Jlomollliter (16), much greater than the
levels produced by injection of the generator eluate in either
animals or patients. None of the patients who received so-
dium nitroprusside in that study experienced any ill effects
(16). The maximal recommended dose of sodium nitro-
prusside administered for hypotensive anesthesia is a total
of 1.5 mg/kg for a period of approximately 2 hours (16).
Approximately 45% of sodium nitroprusside is cyanide (25),
which, if there was no metabolism, would produce a max-
imal recommended cyanide level of 0.675 mg/kg. The
administration of 4 ml of generator eluate (10 clinical doses)
at a concentration of 2.5 mM sodium cyanide would produce
a maximal cyanide level of 0.008 mg/kg, well within the
accepted safety margin.
The mercury breakthrough level with current generators
using thiopropyl sepharose columns is less than 0.0 I% (12).
The lack of significant mercury breakthrough is a crucial
factor, as the administration of significant amounts of mer-
cury would increase the radiation exposure to the patient
and cause problems with imaging; the principal gamma
emissions of mercury-195m are 388 and 560 keY, while
mercury-195 emits 779 and 1,173 keY photons. Approxi-
mately I pg of mercury will be injected into the bloodstream
after the administration of 25 mCi of gold-195m (14), re-
sulting in plasma levels well below the 100 ng/ml of mercury
required to produce toxicity (26).
Since this work was carried out, a new design of column
consisting of controlled pore glass supports (CPG/Lipoam-
ide) has been tested, which has superior flow characteristics
to the previous columns. This permits the use of columns
with lower specific activity. which further reduces the ra-
diation damage to the column.
Clinical results and comparison with technetium-99m
data. The initial clinical results show that first pass radio-
nuclide angiography with gold-195m produces accurate
measurements of left ventricular ejection fraction and im-
ages of wall motion that compare well with technetium-99m
data. In addition, the interobserver and sequential repro-
ducibility of the results are almost identical to the values
reported for technetium-99m first pass studies (17).
Radiation doses to the patients are, of course, substan-
tially lower compared with doses with technetium. The do-
simetric consequences of gold-195m have been estimated
from the eluates obtained from the Byk-Mallinckrodt gen-
erator (Petten, Holland) as 0.21 mrad/mCi to the heart wall
and 0.15 mrad/mCi to the lungs, with much smaller doses
to kidneys and gonads and a negligible total body dose (27).
With a mercury-195m and mercury-195 breakthrough of I
JloCi and 0.2 JloCi, respectively, per I mCi of gold-195m, a
renal dosage of 12.4 mrad/JloCi may be expected (27). With
the administration of six consecutive boluses of gold-195m,
the total radiation burden to the patient has been estimated
as 1.5 rads to the kidneys, a maximum of 0.1 rad to the
gonads and a whole body dose of 0.07 rad (27). The ra-
diation burden from 50 mCi of technetium-99m as pertech-
netate, equivalent to three first pass studies, is 0.5 rad to
the whole body and 5 rads to the kidney. Thus, approximately
15 consecutive gold injections could be administered for the
same radiation burden to the kidneys. The generator de-
scribed in this report permits a mercury breakthrough of
less than 0.01%, and hence. renal exposure will be even
lower than that stated previously. improving the dosimetric
advantage of gold-195m.
Reliability of ejection fraction measurements. The re-
duced radiation exposure is not achieved at the expense of
decreased statistical reliability of the data. With the rnul-
ticrystal camera, the count rates and, hence, statistical re-
liability of the gold studies matched those of technetium.
Although the 262 keY energy of gold-195m is well suited
to the multicrystal camera, it may also be used with standard
single crystal instruments. The count rates obtainable with
a single crystal instrument per mCi of gold are approxi-
mately 45 to 70% of those obtained per mCi of technetium,
depending on the exact energy window chosen and the crys-
tal thickness. Ejection fraction measurements from first pass
studies on such cameras using gold-195m from the Byk-
Mallinckrodt generator have compared favorably with tech-
netium values (28). The mean whole field count rate of 480
counts/s 5 minutes after the first pass study contains counts
not only from residual gold-195m, but also those from other
components, such as the small amount of mercury-195m
that breaks through, and from gold-195, the decay product
of gold-195m.
In the present study. a correction for rapid decay of the
gold was not necessary to achieve accuracy of ejection frac-
tion, even in patients with a low ejection fraction and pro-
longed circulation time. The omission of decay correction
shortens data processing time by approximately 3 minutes
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per study, but it is not yet known whether other count-
dependent indexes of ventricular function, such as count-
based volume measurements (29), will be accurate without
decay correction.
It appears from initial clinical results that gold-195m is
well suited to rapid, sequential first pass studies in human
subjects. The evolutionary changes in left ventricular func-
tion that occur after interventions, such as exercise or the
administration of a drug, may now be assessed at rapid
intervals by first pass radionuclide angiography.
In summary, a new portable generator has been devel-
oped for the production of the short half-life radionuclide
gold-195m. The safety of the product has been established,
and accurate high count rate, first pass studies in patients
are possible. Reproducibility of the measurements is high,
and it is possible to perform rapid, sequential intervention
studies with a low radiation burden to the patients. The use
of this new radionuclide should advance the applicability
of first pass radionuclide angiography in clinical practice.
We are grateful to Cyril Vesey for his help in analysis of the blood samples.
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